WELCOME TO ITOC9!

The 9th ImmunoTherapy of Cancer Conference (ITOC9) to be held virtually from September 22 - 24, 2022 is a European meeting providing a global platform for translational research in the field of immuno-oncology as well as a forum for discussion of early clinical translation and to address its unique challenges.

ITOC9 is organised by the WMA GmbH in scientific cooperation with the ITOC Association, the Tumor Centre in Munich (TZM), the German Cancer Consortium (DKTK), the CECOG Academy, the CAHON as well as the Comprehensive Cancer Center Munich (CCCM) in Munich. The main goal of the series of ITOC conferences is to provide a unique platform for discussions where all those dedicated to the immunotherapy of cancer can exchange their knowledge and latest findings to advance the oncology drug development and delivery.
ITOC9 COMMITTEES

ITOC9 Conference President

• Michael von Bergwelt (LMU, CCC, DKTK, Munich, Germany)

ITOC9 Chairmen of the Scientific Committee

• Sebastian Kobold (Ludwig-Maximilians-Universität, Munich, Germany)
• Volkmar Nuessler (TZM, Munich, Germany)

ITOC9 Scientific Committee

• Niroshana Anandasabapathy (Weill Cornell New York, NY, United States)
• Michael Bergmann (Medical University Vienna, Austria)
• Mascha Binder (Martin Luther University Halle-Wittenberg, Germany)
• Marcus Bosenberg (Yale School of Medicine, New Haven, CT, USA)
• Tanja D. de Gruijl (Cancer Center Amsterdam, The Netherlands)
• Ulrich Jäger (Medical University of Vienna, Austria)
• Andreas Mackensen (Universitätsklinikum Erlangen, Medizinische Klinik 5, Erlangen, Germany)
• Marcela Maus (Harvard Medical School, Massachusetts General Hospital, Boston, MA, USA)
• Chong-Xian Pan (Harvard Medical School, Boston, MA, United States)
• Sine Reker Hadrup (Technical University of Denmark, Experimental & Translational Immunology, Lyngby, Denmark)
• Pedro Romero (Translational Tumor Immunology Group, University of Lausanne, Switzerland)
• Maya Saleh (Director Oncoimmunology Research, Department of Life Sciences and Health, University of Bordeaux, France)
• José Saro (Vice-President, Global clinical Development, Adaptimmune Therapeutics, Abingdon, Oxfordshire, United Kingdom)
• Marion Subklewe (Ludwig-Maximilians-Universität, Munich, Germany)
• Eric Tartour (Hopital Européen Georges-Pompidou, Paris, France)
• Giorgio Trinchieri (Center for Cancer Research, NCI, NIH, Bethesda, MD, United States)
• Christoph Zielinski (Medical University of Vienna, Austria)
THURSDAY, SEPTEMBER 22, 2022

09.00   Registration Opens

10.00 – 10.10 Welcome Address: Michael von Bergwelt, Munich, Germany

10.10 – 11.40 Plenary Symposium 1: Emerging Concepts / New Agents (including Immunometabolism)
Chairs: Stefan Endres, Munich, Germany & Gabriela Wiedemann, Munich, Germany

10.10 – 10.40 01.01 Dissecting and modulating reactive anti-tumor immunity in human cancer
Daniela S. Thommen, Amsterdam, The Netherlands

10.40 – 11.10 01.02 CH13L1: a novel NK cell related immune check point
Maria Rescigno, Pieve Emanuele (Milano), Italy

11.10 – 11.40 01.03 Reprogramming of macrophages by modulators of premetastatic niche formation and their impact on immune
checkpoint blockade
Marisol Soengas, Madrid, Spain

11.45 – 12.15 Coffee Break

12.15 – 13.45 Plenary Symposium 2: Tumor microenvironment and microbiome
Chairs: Marcus Bosenberg, New Haven, CT, USA & Michael Bergmann, Vienna, Austria

12.15 – 12.45 02.01 Investigating the impact of lymphatic transport in immunotherapy
Amanda Lund, New York, NY, USA

12.45 – 13.15 02.02 Immune cell communications in the tumor microenvironment
Thorsten Mempel, Boston, MA, USA

13.15 – 13.45 02.03 Harnessing tumor-derived extracellular vesicles to modulate the TME
Simon Heidegger, Munich, Germany

13.45 – 15.30 Lunch & Poster Viewing

15.30 – 17.30 Plenary Symposium 3: B cells in immunooncology
Chairs: Mascha Binder, Halle, Germany & Eric Tartour, Paris, France

15.30 – 16.00 03.01 From B cells to tertiary lymphoid structures in NSCLC patients
Marie-Caroline Dieu-Nosjean, Paris, France

16.00 – 16.30 03.02 Neoantigen-driven B cells promote CD8 T cell responses
Nikhil Joshi, New Haven, CT, USA

16.30 – 17.00 03.04 Engineering B cells for cancer treatment
Adi Barzel, Tel Aviv University

17.00 – 17.15 03.05 Towards a B cell Vaccine for Tumour expressed Self-Antigens
Fernanda Escobar-Riquelme, Birmingham, United Kingdom

17.15 – 17.30 03.06 Understanding how epitope binding influences antibody dependent complement engagement for
therapy of B-cell malignancies
Sina Bondza, Uppsala, Sweden

17.30 – 19.00 Welcome Reception and Poster Viewing (at the venue)
FRIDAY, SEPTEMBER 23, 2022

08.30 – 09.30  Plenary Symposium 4: Vaccine Therapy  
Chairs: Niroshana Anandasabapathy, New York, NY & Tanja de Gruijl, Amsterdam, The Netherlands

08.30 - 09.00  04.01 IDH directed vaccines in Glioblastoma  
Michael Platten, Heidelberg, Germany

09.00 - 09.30  04.02 The generation of immunostimulatory exosomes programmed by oncolytic viruses  
Brian Lichty, Toronto, ON, Canada

09.30 – 10.30  Plenary Symposium 5: Pro & Contra Sessions for Critical Topics  
Chairs: Florian Bassermann, Munich, Germany, Ulrich Jäger, Vienna, Austria

09.30 – 10.00  05.01 Pro IO combination with chemotherapy  
Mascha Binder, Halle, Germany

10.00 – 10.30  05.02 Contra: IO mono- or combo-therapy shall prevail  
Stéphane Champiat, Villejuif, France

10.30 – 11.15  Coffee Break

11.15 – 13.15  Plenary Symposium 6: Precision Medicine Meets Immunotherapy (Immuno-Monitoring)  
Chairs: Pedro Romero, Epalinges, Switzerland & Chong Xian Pan, Boston, MA, USA

11.45 – 12.15  06.01 Single cell and spatial transcriptomics unravel a NASH-associated innate immunity contexture in hepatocellular carcinoma associated with poor response to immunotherapy  
Maya Saleh, Bordeaux, France

12.15 – 12.45  06.02 Using PET to Image Immune Cell Changes in Response to Therapy  
Elisabeth de Vries, Groningen, The Netherlands

12.45 – 13.00  06.03 Integrative analysis of neuroblastoma by single-cell RNA sequencing identifies the NECTIN2-TIGIT axis as a target for immunotherapy  
Judith Wienke, Utrecht, The Netherlands

13.00 – 13.15  06.05 An activation to memory differentiation trajectory of tumor-infiltrating lymphocytes informs metastatic melanoma outcomes  
Niroshana Anandasabapathy, New York, NY, USA

13.15 – 14.30  Lunch & Poster Viewing

14.30 – 15.00  Satellite Symposium - please see page 14 for details

15.00 – 15.45  Plenary Symposium 7: Lifetime Achievement Award  
Chairs: Michael von Bergwelt, Munich, Germany, Christoph Zielinski, Vienna, Austria

07.01 Presented to Prof. Laurence Zitvogel, Villejuif, France  
Microbiota-centered Interventions to circumvent primary resistance to I-O

15.45 – 16.15  Coffee Break
16.15 – 17.30  **Plenary Symposium 8: “Lost in Translation”**  Chairs: Bastian Schilling, Würzburg, Germany & Maya Saleh, Bordeaux, France

16.15 – 16.45  **08.01 Will vaccination strategies come back of age in melanoma?**  Tanja de Gruijl, Amsterdam, The Netherlands

16.45 – 17.15  **08.02 What T cells see in context of immunotherapy**  Sine Reker Hadrup, Lyngby, Denmark

17.15 – 17.30  **08.03 MHJC-based large-scale screening of anti-tumor T cells in chronic lymphocytic leukemia reveals CD8+ T cells with specificity against the clonotypic B-cell receptor immunoglobulin**  Yogesh Basavaraju, Copenhagen, Denmark

17.30 – 18.30  **Plenary Session 9: Young Researcher Session (from submitted abstracts)**  Chairs: Volkmar Nüssler, Munich, Germany & Sebastian Kobold, Munich, Germany

17.30 – 17.45  **09.01 Armoring anti-HER2 CAR-T cells with C-C-motive receptor 8 (CCR8) and a dominant negative TGF-β receptor (DNR) to enable efficacy in solid tumor models**  Thaddäus Strzalkowski, Munich, Germany

17.45 – 18.00  **09.02 Bispecific antibodies enable synthetic agonistic receptor T cell therapy in melanoma**  Florian Märkl, Munich, Germany

18.00 – 18.15  **09.03 CD122-directed IL-2/anti-IL-2 complexes enhance abscopal responses to radiation combined with anti-PD-1**  Kateryna Onyshchenko, Freiburg, Germany

18.15 – 18.30  **09.04 Secondary resistance to immunotherapy is associated with death and de-differentiation of activated T Cells**  Chen Qing, London, United Kingdom

18.30 - 19.00  **Poster Viewing with Presenters**

20.00  **ITOC9 Conference Dinner**
SATURDAY, SEPTEMBER 24, 2022

08.00 – 09.00  Plenary Symposium 10: Cell Therapy in Solid Tumors
Chairs: Philipp Beckhove, Regensburg, Germany & Justus Weber, Würzburg, Germany

08.00 – 08.30  10.01 Reengineering CAR T cells for optimized efficacy in solid tumors
Sebastian Kobold, Munich, Germany

08.30 – 09.00  10.02 Enabling CAR T cells in solid tumors by check point blockade
Prasad Adusumilli, New York, NY, USA

09.00 – 10.30  Plenary Symposium 11: Cell Therapy in Haematologic Diseases
Chairs: Adrian Gottschlich, Munich, Germany & Tobias Feuchtinger, Munich Germany

09.00 – 09.30  11.01 Single-cell approaches for identifying antigen dependent and independent toxicity in BiTEs and CAR T cells
Caleb Lareau, Standford, CA, USA

09.30 – 10.00  11.02 Novel approaches to cell therapy of myeloma
Andrea Schmidts, Munich, Germany

10.00 – 10.30  11.03 T-cell receptors targeted to leukemia
Johanna Olweus, Oslo, Norway

10.30 – 11.00  Coffee Break

11.00 – 12.45  Plenary Symposium 12: Combination Therapy (with a special focus on local IO)
Chairs: Jose Saro, Abingdon, United Kingdom & Fabian Müller, Erlangen, Germany

11.00 – 11.30  12.04 Synergistic antitumor activity of pan-PI3K inhibition and immune checkpoint blockade in bladder cancer
Chong-Xian Pan, Boston, MA, USA

11.30 – 12.00  12.02 Local immune modulation and tumor ablation
Dr Gosse Adema, Nijmegen, The Netherlands

12.00 – 12.15  12.03 ISB 1442, a first-in-class CD38 and CD47 bispecific antibody innate cell modulator for the treatment of CD38 positive hematological malignancies
Stefano Sammicheli, Lausanne, Switzerland

12.15 – 12.30  12.04 Re-directing CAR-T cells against solid tumors using T-SIGN-mediated antigen delivery and tumor microenvironment reprogramming
Maria Sasso, Abingdon, United Kingdom

12.30 – 12.45  12.05 Tumor targeted innate immune checkpoint blockade for the treatment of Neuroblastoma using Bifunctional antibodies
Fabian Schuurmans, Nijmegen, The Netherlands

12.45 – 13.00  Best Poster Awards & Closing Remarks
Chair: Sebastian Kobold

13.00 – 14.00  Lunch
POSTER PRESENTATIONS

P1 - Emerging concepts / novel agents

P01.01 - PLAP as Target for cancer immunotherapy - Development and Preclinical Characterization of Bispecific Monoclonal Antibody in Colorectal cancer immunotherapy
Norah Alrishedan, Oxford, United Kingdom

P01.02 - Selective induction of cell death in Jurkat cells with recombinant fungal lectin CNL.
Milica Perisic Nanut, Ljubljana, Slovenia

P01.03 - RNAi mediated PD-1 knockdown induces a TCF-1 positive population in activated human CD8 T cells with stem-like associated marker profile
Anna Herbstritt, Munich, Germany

P01.04 - APEX-mediated biotinylation as a potent tool for evaluation of chemokine-receptor interactions and respective binding inhibitors
Antonia Beimert, Munich, Germany

P01.05 - Modelling T Cell migration in 3D vascular beds in a high-throughput microfluidic platform
Luuk de Haan, Oegstgeest, Netherlands

P01.06 - DSP216 blocks HLA-G and CD47 signaling toward immune cells and redesigns the immune suppressive tumor microenvironment
Lisa Jacob, Groningen, Netherlands

P01.07 - Galectin 9 dependent immune evasion machinery as a potential target for personalised immunotherapy of cancer
Vadim Sumbayev, Chatham Maritime, United Kingdom

P2 - Tumor microenvironment and microbiome in Immunotherapy

P02.01 - A bioinformatic analysis: the overexpression and clinical significance of HVEM in liver hepatocellular carcinoma
Kunmin Xiao, Beijing, China

P02.02 - Easy and scalable transfer of an immuno-oncology panel across a wide range of cancer tissue types
Pamela Pulimeno, Tolochenaz, Switzerland

P02.03 - Organization, function and gene expression of tertiary lymphoid structures in pancreatic cancer resembles lymphoid follicles in secondary lymphoid organs and their abundance is related to superior survival
Jonas Lehmann, Cologne, Germany

P02.04 - High-plex spatial immune cell profiling of the tumor microenvironment with ChipCytometry
Thomas Campbell, Saint Louis, United States

P02.05 - How proton pump inhibitors blunt immune checkpoint inhibitors efficacy: a role of the microbiome?
Eloïse Ramel, Bordeaux, France

P02.06 - Investigating the roles of IL-25 and ILC2s in APC-mutation-mediated colorectal cancer
Jane Murphy, Cambridge, United Kingdom

P02.07 - Innate immunity atlas of hepatocellular carcinoma unravels the differentiation hierarchy of myeloid NK cells and MDSCs
Domitille Chalopin, Bordeaux Cedex, France
POSTER PRESENTATIONS

P02.08 - The role of the inflammasome in the spatiotemporal evolution of the immune cell landscape in post-resection glioblastoma
Sébastian Lillo, Bordeaux, France

P02.09 - Integrated single-cell profiling dissects cell-state-specific enhancer landscapes of human tumor-infiltrating T cells
Christian Schmidl, Regensburg, Germany

P3 - Vaccine Therapy
P03.01 - Development of a multi-tumour antigen vaccine for hard-to-treat cancers
Carles Puig Saenz, Nottingham, United Kingdom

P03.02 - A mutated prostatic acid phosphatase (PAP) peptide-based vaccine induces PAP-specific CD8+ T cells with ex vivo cytotoxic capacities in HHDII/DR1 transgenic mice
Jubini Thomas, Nottingham, United Kingdom

P03.03 - Active immunization against human endogenous retrovirus type K (HERV-K) as an immunotherapeutic strategy against solid tumors
Peter Holst, COPENHAGEN, Denmark

P03.04 - Combined SCIB1 DNA vaccine and PD-1 checkpoint blockade for the treatment of intracranial tumours
Stephanie McArdle, Nottingham, United Kingdom

P03.05 - Vaccine immunotherapy against human endogenous retrovirus: a focus on anti-herv-k antibodies
Amaia V. Bermejo, Copenhagen, Denmark

P03.06 - Tumor associated antigens and pathogen antigens: friends or foes
Luigi Buonaguro, NAPOLI, Italy

P03.07 - Towards HERV-H Env protein based tumor stratification and intervention strategies
Jasmin Gille, Regensburg, Germany

P03.08 - Neoantigenic versus multi-antigenic personalized B16 melanoma vaccines comparison according to anti-tumor T cell response intensity
Ekaterina Ushakova, Moscow, Russian Federation

P4 - Precision Medicine Meets Immunotherapy (Immuno-Monitoring)
P04.01 - Volatile profiling using an eNose allows differentiation of volatile phases derived from serum, DC, or MLC culture supernatants from healthy or leukemic samples
Helga Schmetzer, Munich, Germany

P04.02 - A high sensitivity, tumor-informed liquid biopsy platform, designed to detect minimum residual disease at part per million resolution
Maik Pruess, Menlo Park, United States

P04.03 - Cancer Immunotherapies, Companion Diagnostics and Precision Medicine
Nora Cascante-Estepa, Bonn, Germany
P5 - Reverse translation
P05.01 - Platelets role in immunotherapy response in non-small cell lung cancer
Chiara Colarusso, Fisciano, Italy

P6 - Cell Therapy in Solid Tumors
P06.01 - ROR1-CAR T-cells as novel treatment strategy for anaplastic thyroid carcinoma
Dmitry Chernyakov, Halle (Saale), Germany

P06.02 - Anti-nucleolin CAR (chimeric antigen receptor)-T cell targeting Triple-Negative Breast Cancer - critical parameters in CAR-T cells generation
Teresa Abreu, Coimbra, Portugal

P06.03 - T cell mediated killing of neuroblastoma is inhibited by secreted MIF and MDK
Josephine Strijker, Utrecht, Netherlands

P06.04 - Immune responses against shared antigens are common in esophageal-gastric cancer and can be enhanced using CD40-activated B cells
Martin Thelen, Cologne, Germany

P7 - Cell Therapy in Haematologic Diseases
P07.01 - THE POTENTIAL ROLE OF EXTRACELLULAR VESICLE-DERIVED SMALL RNAs IN AML RESEARCH AS NON-INVASIVE BIOMARKER
Lin Li, München, Germany

P07.02 - Control leukemia by inducing anti-cancer immune reactivity in vivo? - Potential of a DC-triggered mechanism
Helga Schmetzer, Munich, Germany

P8 - Combination Therapy
P08.01 - Combined approach of Adoptive Cell Therapy with Cytokine-Induced Killer cells retargeted with immunotools against HER-2-expressing breast cancer
Annavera Ventura, Padova, Italy

P08.02 - Liposomal doxorubicin enhances the radiation-induced abscopal effect by promoting the release of mitochondrial DNA
Liqun Wang, Freiburg im Breisgau, Germany

P08.03 - Interleukin-12 gene electrotransfer as an adjuvant immunotherapy to electrochemotherapy
Katja Ursic Valentinuzzi, Ljubljana, Slovenia

P08.04 - Phototherapy with cancer-specific nanoporphyrin potentiates immunotherapy in bladder cancer
Chong-xian Pan, Boston, United States

P08.05 - Lentiviral protein Vpx delivery systems as potential weapons to improve cytarabine treatment response against acute myeloid leukemia
Ramya Nair, Munich, Germany

P08.06 - Use of luciferase-labeled target cells to explore immune cell killing in high throughput format
Carla Castro, Freiburg, Germany
POSTER PRESENTATIONS

P08.07 - Identification of stress granule formation as a therapeutic target in chemotherapy treated colorectal cancer
Annalena Renner, Vienna, Austria

P08.08 - Immunomodulation by Lactate dehydrogenase C indicates a potential new opportunity for combination therapy
Adviti Naik, Doha, Qatar

P08.09 - Genome-wide CRISPR/Cas9 screening for identification of tumor-intrinsic mechanisms of resistance to anti-PD1 therapy in high-risk neuroblastoma
Divya Nagarajan, Uppsala, Sweden

P08.10 - Combining STING-agonist with radiotherapy remodels tumor immune microenvironment in human malignant pleural effusions
Rebecca Zimbauer, Vienna, Austria

P9 - Young Researcher Session

P09.01 - Single-cell transcriptomic atlas-guided development of chimeric antigen-receptor (CAR) T cells for the treatment of acute myeloid leukemia
Adrian Gottschlich, Munich, Germany

P09.02 - Modular P329G-binding CAR T cells engineered to recognize human effector-silenced antibodies carrying a P329G Fc-mutation for targeting of solid tumor antigens
Sophia Stock, Munich, Germany

P09.03 - Activation of IL-22 signaling correlates with higher CD155 expression and stratifies poor outcomes of early-stage lung and breast cancer patients
Daria Briukhovetska, Munich, Germany

P09.04 - Cathepsin V inhibition prevents the activation of cystatin F and increases immune cell cytotoxicity
Emanuela Senjor, Ljubljana, Slovenia

P09.05 - Exploring the therapeutic vulnerabilities of cathepsin S hyperactive tumors
Johannes Hildebrand, München, Germany

P09.06 - A Toll-Like Receptor agonist represents a potential adjuvant in fourth generation CAR-T cell-based immunotherapy
Jolanda Maş, Candiolo, Italy

P09.07 - Deciphering the nature of the cooperation between monocytes/macrophages and CD8+ T cells during immunotherapy-induced tumor regression
Anaïs Vermare, Paris, France

P09.08 - The tumor immune microenvironment of head and neck cancer in relation to anatomical site classification
Tara Muijlwijk, Amsterdam, Netherlands

P09.09 - A CAR-T cell-based approach for the treatment of malignant T cell diseases
Maximilian Funk, Vienna, Austria

P09.10 - Dysregulated Expressions of Inhibitory Checkpoint Molecules and Their Ligands on T-Cells and Blasts in AML Relapses After Stem Cell Transplantation (SCT)
Sophia Bohlscheid, Munich, Germany
POSTER PRESENTATIONS

P09.11 - Anti-proliferative effects of gut microbial metabolites on human gastric adenocarcinoma cells and their potential synergy with dexamethasone
Deep Jyoti Bhuyan, Penrith, Australia

P09.12 - Hereditary homozygosity and allelic imbalance of HLA as common immune escape mechanisms in esophageal adenocarcinoma
Maria Garcia Marquez, Cologne, Germany

P09.13 - Immune geospatial profiling and characterization of glioma microenvironment after adoptive cell therapy shows differentially expressed antigen processing and cross-presentation gene signatures
Laura Falceto Font, Gainesville, United States

P09.14 - The role of IDO1 and cellular senescence in the efficacy of PD-1 pathway blockade and radiotherapy in aged mice with glioblastoma
Evridiki Asimakidou, Chicago, United States

P09.15 - Patient-derived head and neck tumor slice cultures - a versatile tool to study oncolytic virus action
Melissa Mayr, Innsbruck, Austria

P09.16 - MelARV vaccine with mutations in the immunosuppressive domain elicits increased immunity and elimination of established tumors in mice
Joana Daradoumis, Copenhagen, Denmark

P09.17 - High-resolution of neoantigen-specific T cell receptor activation patterns - moderate stimulation predicts sustained anti-tumor-response
Franziska Füchsl, München, Germany

P09.18 - TNF induction in essential for oncolytic influenza A virus induced cancer regression and tumor associated macrophage repolarization
Jakob Homola, Vienna, Austria

P09.19 - Complex primary organoid cultures to dissect immunogenic effects of therapy on macrophages in a precision medicine-like approach
Julijan Kabiljo, Wien, Austria

P09.20 - Impact of TCR independent, KIR-HLA-C interactions on KIR+CD8+ T cells in health and disease
Janine Kemming, Kongens Lyneby, Denmark

P09.21 - Modelling the spatial dynamics of oncolytic virotherapy in the presence of virus-resistant tumor cells
Darshak Bhatt, Groningen, Netherlands

P09.22 - Toward a rational design of immunonanotherapies
Vincent Mittelheisser, Strasbourg, France

P09.23 - Immune cell infiltration as a novel marker for predicting patient outcome in nephroblastoma
Lukas Watzke, Vienna, Austria
Projection and Technical Setting

PowerPoint is the only communication tool available in the session hall. Overhead projection, slide projection or flipcharts are not available.

• Speakers are kindly asked to observe that only the computer provided by the venue may be used for showing your presentations. PowerPoint presentations can be checked and handed in at the speakers’ preview desk or uploaded via USB Stick in the lecture room directly.

• All PowerPoint presentations should be checked/handed in at least 2 hours before the session starts.

• If you are doing more than one speech during the congress, you may upload all your presentations at the same time and they will be sent to the session hall at the time of your session.

• The PowerPoint handling and distribution system is optimized for MS PowerPoint 2007 (Office 2007) and ”*.pdf” (Adobe Acrobat)-files. The uploading of “DVD-Movies” is not supported.

• The supported data media is USB-Memory Key. You may want to carry a second key/CD as a back-up in case there is any insoluble technical problem. All needed files (including the movie files!) - have to be saved on the data media. Presentations can also be taken off speakers notebooks at the Preview centre.

• The fonts that are used in the presentations should be ”Latin-based fonts”. If the speaker needs special fonts, they should be stored as ”embedded fonts” with the presentation (File -> save as ”name of presentation” and under ”tools” ->save options mark the checkbox ”embed True type fonts” and select ”embed all characters”).

• When using mathematical symbols please use these which are available under Latin fonts (unicode or DOS: Western Europe). These can be shown without any problems in Office 2007.

• As format for embedded movies ”MPEG2 - movies” are preferred (but can also be ”.avi”, ”.wmv”). If Codecs are used, the Code package DIVx in the current version, which can be found under www.divx.com, should be chosen.

• Presentations should be saved as ”*.ppt”, ”*.pptx” (=PowerPoint) or ”*.pps”, ”*.ppsx” (=PowerPoint Slideshow) - file and movies as separate files on the data media.

• The computers and projectors will be set up and optimised for resolution ratio 16:9.

• These guidelines should be seen as a matter of improving the effectiveness of the preview system and in consequence also the speakers comfort.

Speaking Time

The chairpersons will be strict in allowing no more than the time allotted to presentations and discussions following the presentations. Remember to allow some time for the changeover of speakers and chairperson’s introduction, and for questions and discussion.

Commercial Disclosure Information

Due to EACCME regulations, authors are requested to disclose possible conflicts of interest on the first slide. A conflict of interest is any situation in which a speaker or immediate family members have interests, and those may cause a conflict with the current presentation. Conflicts of interest do not preclude the delivery of the talk, but should be explicitly declared. These may include financial interests (e.g. owning stocks of a related company, having received honoraria, consultancy fees), research interests (research support by grants or otherwise), organisational interests and gifts.
Maik Pruess PhD
Senior Field Application Scientist
Personalis, Inc.

Personalis NeXT Platform
Enabling the future of precision oncology with comprehensive, unprecedented tumor profiling solutions for both tissue and liquid biopsy

• Combining highly sensitive, exome-scale DNA and RNA sequencing with advanced analytics, ImmunoID NeXT™ provides a multidimensional view of the tumor and the tumor microenvironment from a single tumor sample preparation

• A clinical case study in a cohort of late-stage melanoma patients demonstrating how the integration of neoantigen burden, HLA LOH, and Antigen Presentation Machinery (APM) mutational data formed a composite biomarker that more accurately predicted response to checkpoint blockade than other markers

• In parallel, specimens may be processed using NeXT Personal™, an ultrasensitive tumor-informed liquid biopsy assay, designed to detect molecular residual disease and cancer recurrence at the earliest timepoints, with simultaneous variant tracking for additional insight into disease progression
Advanced diagnostics for today...

...a pathway to new treatment decisions tomorrow

The NeXT generation of comprehensive genomic profiling

**ImmunoID NeXT**
- Comprehensive WES/ WTS immuno-genomic profiling
- Delivering today’s biomarkers while discovering those that will matter tomorrow

**NeXT Personal**
- Ultra-sensitive Tumor-Informed MRD & Recurrence Detection
- Unique combination of tumor-specific variant and clinically relevant driver variants tracking

**NeXT Dx**
- CLIA LDT diagnostic with tumor profiling and immune response reporting for oncologists

Visit us in stand # 18 at iTOC 2022.

personalis.com
FLOORPLAN
## EXHIBITORS

<table>
<thead>
<tr>
<th>EXHIBITOR</th>
<th>STAND #</th>
</tr>
</thead>
<tbody>
<tr>
<td>Canopy Biosciences</td>
<td>2</td>
</tr>
<tr>
<td>Mabtech</td>
<td>4</td>
</tr>
<tr>
<td>Lumicks</td>
<td>6</td>
</tr>
<tr>
<td>Miltenyi Biotec</td>
<td>8</td>
</tr>
<tr>
<td>Schaefer Technologie/TissueGnostics</td>
<td>10</td>
</tr>
<tr>
<td>Novogene</td>
<td>12</td>
</tr>
<tr>
<td>Singleron Biotechnologies</td>
<td>14</td>
</tr>
<tr>
<td>Lunaphore Technologies</td>
<td>16</td>
</tr>
<tr>
<td>Personalis</td>
<td>18</td>
</tr>
<tr>
<td>Agilent Technologies</td>
<td>20</td>
</tr>
<tr>
<td>Standard BioTools</td>
<td>22</td>
</tr>
<tr>
<td>BiolVT</td>
<td>26</td>
</tr>
<tr>
<td>Akoya Biosciences</td>
<td>28</td>
</tr>
<tr>
<td>OLS OMNI Life Science</td>
<td>30</td>
</tr>
<tr>
<td>Research Donors</td>
<td>32</td>
</tr>
</tbody>
</table>
GENERAL INFORMATION

ORGANIZER

WMA GmbH
Conference & Society Management
• Contact: Catherine Tomek
• E-mail: itoc@wma.co.at
• Tel.: +43 1 405 13 83 18
• Website: www.wma.co.at

SPONSORSHIP AND EXHIBITION MATTERS

Rose International
Exhibition Management & Congress Consultancy bv
• Contact: Flora van Laer
• E-mail: fvanlaer@rose-international.com
• Tel.: +31 70 383 8901

CONFERENCE VENUE

Klinikum der Universität München
Campus Großhadern
Lecture Room 3
Marchioninistrasse 15
80336 Munich, Germany

HOW TO REACH THE VENUE

Subway:
Metro Line U6 from Marienplatz to the final stop
at the Klinikum Großhadern
Bus: Main Bus Line Nr. 56
Regional Buses 266 and 269
See also https://efa.mvv-muenchen.de

Cancellations and Refunds
Registration fees may be refunded if written cancellation has been received as follows:
– until July 15, 2022: 50% refund
– after July 15, 2022: no refund
The cancellation will not be effective until a written acknowledgement from the Congress Office is received. In the case of over-payment or double payment, refund requests must be made in writing and sent to the Congress Office by e-mail. No refunds will be granted for unattended events or early termination of attendance, in case of cancellation of speakers or any other incidents during the conference, which are beyond the control of the conference organisers.
No exceptions to the refund policy can be made, including health or family issues. By registering for ITOC9, participants agree that neither the organising committee nor the Congress Office assume any liability whatsoever.

Certificate of Attendance
Confirmations of attendance will be issued after the conference to all registered participants after completion of an online survey.

CME Credits
The 9th Immunotherapy of Cancer Conference, Munich, Germany (September 22 - 24, 2022) has been granted 11 European CME credits (ECMEC) by the European Accreditation Council for Continuing Medical Education (EACCME). European Accreditation is granted by the EACCME in order to allow participants attending the above mentioned activity to validate their credits in their own country.
GENERAL INFORMATION

Badges
For security reasons, badges will be checked upon access of the conference areas. Delegates are therefore requested to wear their badge at all times during the conference.

Catering
Coffee breaks and the welcome reception have been scheduled in the exhibition area. Exact times are listed in the programme overview.

Certificate of Attendance
The 9th ImmunoTherapy of Cancer Conference is happy to introduce a digital CME acquisition system. You will be able to view and print a confirmation stating the according number of CME credits after finishing a survey requested by the UEMS. The link to the survey will be sent to all registered participants right after the conference.

Currency
The official currency of Germany is the Euro (EUR).
1 EUR = 1,00 USD = 0,86 GBP = 144 JPY = 0,96 CHF = 1,47 AUD = 1,31 CAD
as per date of printing

Exhibition
The exhibition is held on level 2 next to the main lecture room hall 3. Entrance is free for registered delegates but limited to healthcare professionals, press and exhibitors.

Insurance
By registering to the ITOC9, participants agree that neither the organising committee nor the congress office assume any liability whatsoever. Participants are requested to make their own arrangements for health and travel insurance. The conference fee does not include insurance.

Language & Translation
The official language of the conference is English. No simultaneous translation is provided.

Liability
In registering for ITOC9 participants agree that neither the organising committee nor the congress office assume any liability whatsoever. Participants are requested to make their own arrangements in respect of health and travel. Furthermore, the organisers cannot assume any liability for changes in the programme due to external or unforeseen circumstances and force majeure.

Opening hours of the registration desk
September 22, 2022: 09.00 - 19.00 hrs CEST
September 23, 2022: 08.00 - 19.00 hrs CEST
September 24, 2022: 07.30 - 14.00 hrs CEST

Registration Details
Registration Fees in EUR (all fees include 19% German VAT)

<table>
<thead>
<tr>
<th></th>
<th>Early Bird</th>
<th>from April 1, 2022 to July 31, 2022</th>
<th>From August 1 - September 11, 2022 and On-Site</th>
</tr>
</thead>
<tbody>
<tr>
<td>Academia</td>
<td>EUR 465,-</td>
<td>EUR 565,-</td>
<td>EUR 665,-</td>
</tr>
<tr>
<td>Junior Participant(1)</td>
<td>EUR 115,-</td>
<td>EUR 145,-</td>
<td>EUR 190,-</td>
</tr>
<tr>
<td>Industry</td>
<td>EUR 765,-</td>
<td>EUR 865,-</td>
<td>EUR 965,-</td>
</tr>
<tr>
<td>Foundations &amp; Charities</td>
<td>EUR 240,-</td>
<td>EUR 290,-</td>
<td>EUR 340,-</td>
</tr>
<tr>
<td>Press / Media</td>
<td>no fee</td>
<td>no fee</td>
<td>no fee</td>
</tr>
</tbody>
</table>

(1) The “Junior Participant” registration is available for Students under 30 years of age. Please provide a copy of a student ID at the moment of your registration either by fax to +43 1 405 13 83 918 or upload a jpeg, jpg, gif, bmp or png. Payments were to be made without charges to the beneficiary. Any bank charges will be claimed. Please be informed that onsite payment by creditcard is preferred.

COVID19
Please be informed that
GENERAL INFORMATION

What is covered by the registration fee?
- Admission to all scientific sessions
- Admission to all poster sessions
- Admission to the exhibition
- Abstract book and programme
- Coffee Breaks
- Welcome Reception

Twitter
The 9th ImmunoTherapy of Cancer Conference is present on Twitter @ITOCconference. We invite you to follow us on Twitter and to engage and discuss with your colleagues.

Photographs, Video-Streaming, etc.
The Organiser may without the further consent of the participants use and release pictures and videos taken during the Conference for reports of the Conference and/or in future marketing materials. By registering to this conference attendees agree that photographs or sound or video recordings taken during the conference that could include recognizable images or voices of those in attendance may be posted on the conference website. All recordings are treated sensitively and discreetly. Names will not be published. The Conference is held in a public space, therefore we do not prohibit participants, exhibitors, sponsors, or news organisations from photographing, video or audio-taping some Conference activities. The organiser reserves the right to use images taken at the Conference with your photograph and/or likeness on social media and/or in future marketing materials. The organiser is NOT responsible for individual attendee’s use of your image or likeness.

Policies
ITOC9 is accessible to all registered delegates. Children and members of the public are not permitted in the exhibition area or any room hosting an industry activity. In addition, the ITOC9 conference asks delegates and faculty to refrain from taking children and accompanying adults to any sessions or practical demonstrations. In the event that children are required to enter the conference centre, they should be supervised by an adult at all times and observe the restrictions that apply to limited access areas. In the event that a member of public is invited to participate in the ITOC9 conference scientific programme, they should be accompanied by a qualified healthcare professional or ITOC9 representative observing the ITOC9 restrictions where appropriate.

Poster Removal
The organisers cannot assume any liability for loss or damage of posters displayed in the poster area. Posters that were not removed after the end of the conference, will be removed and will neither be kept nor mailed to the author after the meeting.

Safety - Crime
Visitor safety is generally adequate, like in any other major European city. You can walk everywhere using common sense. Pick pocketing in heavily visited tourist zones or in public transport lines might be a concern. Unfortunately experience has shown that some basic precautionary measures should always be kept in mind in any city:
- Do not carry important items like flight tickets, passports etc. with you when visiting the conference or strolling through the city, leave them in the hotel safe during your stay. Rather carry a Xerox copy of your passport or an identity card with you.
- Try not to carry all documents, money, credit cards and other essential items and valuables in one bag. If it is lost or stolen, everything will be gone and might be difficult to replace on short notice, especially passports and visa to return to your country of residence.
- Take off your name badge when leaving the conference venue, it will make you easily identifiable as a tourist.

Smoking Policy
ITOC9 is a “No-smoking-Conference”.

20 SCIENTIFIC PROGRAM - 9TH IMMUNOTHERAPY OF CANCER CONFERENCE www.itoc-conference.eu
GENERAL INFORMATION

Social Media Policy
ITOC9 supports the use of social media around its conferences and events in order to network with colleagues and friends attending the meeting. Please do however respect the ITOC9 social media guidelines, including the following:

DOs:
• Follow ITOC9 on Twitter (@ITOCconference) and use the meeting hashtag to follow the latest updates and join in the conversation about the conference.
• You may tweet about content of the talks, unless the speaker explicitly asks you not to share either the entire talk or specific details or slides.
• Communicate in a respectful and considerate way, and show your criticism in a fair, constructive and professional manner.
• Do remember that people who will read your postings or tweets are not necessarily professionals, but also patients, policymakers, members of the media, and the general public.

DON'Ts:
• The use of photography in oral and poster sessions at the ITOC9 conferences is allowed, unless indicated differently by the author on one or all of their slides or their poster. Hence posting pictures or videos of presentations (in parts or as a whole) carrying a “no picture” symbol on any social media platform, blogs, or websites, etc., is strictly prohibited.
• Do not capture or redistribute data presented at conferences as this may jeopardise the subsequent publication of the data in a scientific journal. Powerpoint presentations marked with a “no picture” symbol must not be photographed under any circumstances.
• Do respect journal embargo policies and the work of your colleagues!
• Refrain from engaging in personal attacks or showing rude behaviour.
• Offensive and disrespectful behaviour, sales-oriented, self-promoting, or otherwise inappropriate comments will not be tolerated.
• Participants should not post copyrighted or trademarked material or material protected by other intellectual property rights.

The views and opinions posted on ITOC9’s social media do not necessarily reflect the views, opinions, or policies of the ITOC association, its Board or membership. The ITOC reserves the right to remove comments it deems to be inappropriate.

Staff
If you should have any questions, the congress staff will be pleased to help you.

WiFi
Free WiFi (Bayern WLAN) is available for participants

For further general information, please also see www.itoc-conference.eu
ACKNOWLEDGEMENTS

The organisers gratefully acknowledge the support of the following institutions and companies:
Spatial Biology Without Limits

Meet CellScape™
The Next Generation of ChipCytometry™ Instrumentation

CellScape™ is an end-to-end solution for highly multiplexed spatial omics. Combining an advanced, purpose-built imaging system with easy-to-use fluidics for walk-away automation, the CellScape™ system accelerates exploration in the rapidly evolving field of spatial biology.

CanopyBiosciences.com/CellScape

Visit us at Booth #2 to learn more!